Immucell vs Intellia Therapeutics: revenue, profit, margins and growth compared
Immucell brought in $27.6M of revenue in fiscal 2025, Intellia Therapeutics $67.7M in fiscal 2025. Revenue changed by +4.3% at Immucell and +16.9% at Intellia Therapeutics on the year before, so Intellia Therapeutics grew faster. Immucell kept -3.8% of its revenue as net profit, Intellia Therapeutics -609.9%. Free cash flow was $1.2M at Immucell and -$395.9M at Intellia Therapeutics.
Fiscal years as each company reports them; the two may end in different months.
Questions about Immucell and Intellia Therapeutics
Which is bigger by revenue, Immucell or Intellia Therapeutics?
Intellia Therapeutics is bigger by revenue: $67.7M in fiscal 2025, against $27.6M for Immucell in fiscal 2025.
Which keeps more of its revenue as profit, Immucell or Intellia Therapeutics?
Immucell had a net margin of -3.8% in fiscal 2025; Intellia Therapeutics had -609.9% in fiscal 2025.
Which grew revenue faster, Immucell or Intellia Therapeutics?
In their latest fiscal years revenue changed by +4.3% at Immucell and +16.9% at Intellia Therapeutics.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.